Recent regulatory filings have painted a revealing picture of sentiment around defense contractor Hensoldt. In a notable display of confidence, Chief Executive Oliver Dörre purchased shares privately, while investment giant BlackRock marginally increased its stake. These moves come at a pivotal moment for the company, which is navigating record demand against significant production bottlenecks. This dynamic raises key questions about the stock’s future trajectory.
Operational Momentum Meets Capacity Walls
The company’s recently published figures for 2025 underscore its operational strength. Order intake surged by 62% to reach €4.71 billion, propelling the order backlog to €8.83 billion, a 33% increase. Revenue followed suit, climbing 9.6% to €2.455 billion. Profitability also improved, with adjusted EBITDA hitting €452 million, translating to a margin of 18.4% and exceeding the company’s own guidance of at least 18%. Adjusted free cash flow rose to €347 million.
Despite these robust figures, market reaction has been measured. The core issue is a capacity constraint: Hensoldt is witnessing unprecedented demand but cannot convert orders into revenue as quickly as desired. This challenge has directly impacted forward-looking guidance, making the 2026 outlook a focal point for investor concern.
Confidence Signals from a CEO and a Major Investor
Details from Directors’ Dealings filings show CEO Oliver Dörre acquired 1,000 shares at an average price of €75.25, representing a total investment of €75,250. Shortly thereafter, an updated voting rights notification revealed that BlackRock’s holding now stands at 5.06% of voting rights. This stake comprises 2.96% via shares and 2.09% via financial instruments, up slightly from a previously reported 5.01%.
The market often scrutinizes such signals closely, especially when they occur in proximity to significant financial announcements, as is the case here.
Revised 2026 Outlook and Strategic Expansion Plans
For the 2026 fiscal year, Hensoldt has provided revenue guidance of approximately €2.75 billion and an adjusted EBITDA margin between 18.5% and 19%. The company noted that the midpoint of its revenue forecast sits about two percent below the current analyst consensus. Management reaffirmed its target for a book-to-bill ratio in the range of 1.5x to 2.0x, indicating that strong demand is not the issue—execution is.
To address these production limitations, a substantial expansion is underway. The firm plans to create roughly 1,600 new positions in 2026, expanding its workforce of approximately 9,000 employees by nearly 18%. Furthermore, it has earmarked around €1 billion in capital expenditures for the period from 2025 to 2027 to scale up capacity, primarily for German defense contracts. In a show of stability, the supervisory board has extended CEO Oliver Dörre’s contract ahead of schedule through the end of 2031.
Market Performance and Forthcoming Milestones
The current market valuation reflects this complex mix of strong fundamentals and near-term hurdles. Shares closed at €78.75 on Wednesday. This price sits roughly 5.5% below the 50-day moving average of €83.30 and is approximately 31.6% below the 52-week high of €115.10.
Key dates for investors are already scheduled. The annual report is due on 26 March 2026, followed by quarterly figures on 6 May 2026. For the annual general meeting, a dividend of €0.55 per share will be proposed. The ex-dividend date is set for 25 May 2026, with payment scheduled for 27 May 2026.
